Skip to content
10-Q

Quarterly Report

Panbela Therapeutics, Inc.

0001437749-24-026462

← back to feed
Filed
Aug 13, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 9, 2024 4.85M sh
Operating Cash Flow Q2 2024 · Jun 30, 2024 −$10.37M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$15.49M
Long Term Debt Q2 2024 · Jun 30, 2024 $3.19M
Long Term Debt Q2 2024 · Dec 31, 2023 $4.19M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $59K
Cash And Equivalents Q2 2024 · Dec 31, 2023 $2.58M
Stockholders Equity Q2 2024 · Jun 30, 2024 −$10.57M
Stockholders Equity Q2 2024 · Mar 31, 2024 −$3.19M
Stockholders Equity Q2 2024 · Dec 31, 2023 −$4.71M
Stockholders Equity Q2 2024 · Jun 30, 2023 $4.8M
Stockholders Equity restated Q2 2024 · Mar 31, 2023 $2.53M
Stockholders Equity Q2 2024 · Dec 31, 2022 −$8.05M
Current Liabilities Q2 2024 · Jun 30, 2024 $16.79M
Current Liabilities Q2 2024 · Dec 31, 2023 $12.32M
Total Liabilities Q2 2024 · Jun 30, 2024 $19.98M
Total Liabilities Q2 2024 · Dec 31, 2023 $16.51M
Current Assets Q2 2024 · Jun 30, 2024 $772K
Current Assets Q2 2024 · Dec 31, 2023 $3.06M
Total Assets Q2 2024 · Jun 30, 2024 $9.41M
Total Assets Q2 2024 · Dec 31, 2023 $11.8M
Eps Basic Q2 2024 · Jun 30, 2024 −$1.47
Eps Basic Q2 2024 · Jun 30, 2024 −$3.58
Eps Basic restated Q2 2024 · Jun 30, 2023 −$159.15
Eps Basic restated Q2 2024 · Jun 30, 2023 −$441.77
Sga Expense Q2 2024 · Jun 30, 2024 $1.11M
Sga Expense Q2 2024 · Jun 30, 2024 $2.31M
Sga Expense Q2 2024 · Jun 30, 2023 $1.64M
Sga Expense Q2 2024 · Jun 30, 2023 $3M
Rd Expense Q2 2024 · Jun 30, 2024 $7M
Rd Expense Q2 2024 · Jun 30, 2024 $12.52M
Rd Expense Q2 2024 · Jun 30, 2023 $4.23M
Rd Expense Q2 2024 · Jun 30, 2023 $7.75M
Net Income Q2 2024 · Jun 30, 2024 −$7.14M
Net Income Q2 2024 · Jun 30, 2024 −$14.26M
Net Income Q2 2024 · Mar 31, 2024 −$7.12M
Net Income Q2 2024 · Jun 30, 2023 −$5.83M
Net Income restated Q2 2024 · Jun 30, 2023 −$10.95M
Net Income restated Q2 2024 · Mar 31, 2023 −$5.12M
Operating Income Q2 2024 · Jun 30, 2024 −$8.1M
Operating Income Q2 2024 · Jun 30, 2024 −$14.83M
Operating Income Q2 2024 · Jun 30, 2023 −$5.88M
Operating Income Q2 2024 · Jun 30, 2023 −$10.75M